ArticleAmerican journal of translational research2019
MicroRNA-940 inhibits glioma cells proliferation and cell cycle progression by targeting CKS1.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework.NPJ systems biology and applications · 2024Article
- Polyphenols Modulate the miRNAs Expression that Involved in Glioblastoma.Mini reviews in medicinal chemistry · 2024Review
- miR-940 modulates CD47 to suppress biological functions of lung adenocarcinoma cells.American journal of cancer research · 2024Article
- miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGFβ2 signaling pathway.Cancer biology & therapy · 2023Article
- Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors.Stem cell research & therapy · 2022Review
- Role of Circular RNA in Brain Tumor Development.Cells · 2022Review
- Non-coding RNAs and glioblastoma: Insight into their roles in metastasis.Molecular therapy oncolytics · 2022Review
- Zinc finger Asp-His-His-Cys palmitoyl -acyltransferase 19 accelerates tumor progression through wnt/β-catenin pathway and is upregulated by miR-940 in osteosarcoma.Bioengineered · 2022Article
- DecreasedTranslational lung cancer research · 2021Article
- miR-940 is a new biomarker with tumor diagnostic and prognostic value.Molecular therapy. Nucleic acids · 2021Review
- Glioblastoma and MiRNAs.Cancers · 2021Review
- Article
- MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer.Frontiers in oncology · 2021Article
- MicroRNA-136-3p inhibits glioma tumorigenesis in vitro and in vivo by targeting KLF7.World journal of surgical oncology · 2020Article
- The Role of Non-Coding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells.Frontiers in oncology · 2020Review
- The Hsa_circ_0091579/miR-940/TACR1 Axis Regulates the Development of Hepatocellular Carcinoma.Cancer management and research · 2020Article
- MicroRNA-623 Inhibits Epithelial-Mesenchymal Transition to Attenuate Glioma Proliferation by Targeting TRIM44.OncoTargets and therapy · 2020Article
- Transferrin Receptor-Targeted PEG-PLA Polymeric Micelles for Chemotherapy Against Glioblastoma Multiforme.International journal of nanomedicine · 2020Article
- Downregulation of Hsa_circ_0000735 Inhibits the Proliferation, Migration, Invasion, and Glycolysis in Non-small-cell Lung Cancer by Targeting miR-940/BMPER Axis.OncoTargets and therapy · 2020Article
- EIF3J-AS1 promotes glioma cell growth via up-regulating ANXA11 through sponging miR-1343-3p.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most frequently occurred malignant human tumor that arise in brain with a poor prognosis. microRNAs (miRNAs) are vital small molecules during GBM initiation and progression. However, the expression of miR-940 and its potential function in GBM remain poor. Our study demonstrated that miR-940 was dramatically decreased in GBM cells and glioma tissues. Introduction of miR-940 significantly repressed proliferative ability of GBM cells. Notably, treatment of miR-940 dramatically suppressed tumor growth in an animal model, accompanied by decreased Ki67 expression. Functional experiments showed CKS1 as a target of miR-940, knockdown of CKS1 significantly induced the cell cycle arrest and restrained GBM cells proliferation, consistent with miR-940 treatment. Furthermore, reintroduction of CKS1 into glioma cells effectively rescued the tumor suppressive effect of miR-940. Correlation analysis indicated that miR-940 expression was inversely related to CKS1 mRNA levels in NBTs and gliomas. Together, miR-940/CKS1 signaling may be required for GBM progression and provide a new insight in diagnosis and prognosis of GBM patients.
Indexed as
Identifiers
31497204PMC6731435W2992283979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.